Children diagnosed with inflammatory bowel disease (IBD) face a significantly higher risk for venous thromboembolism (VTE) ...

The top 5 biosimilar conference articles in 2024 highlight significant progress in the biosimilar landscape, including ...

PFE issues its financial guidance for 2025. MRK and ABBV announce M&A deals. SNY/TEVA's IBD drug succeeds in a phase IIb ...

Researchers have uncovered potentially diagnostic gut microbiome signatures and metabolic pathways associated specifically ...

Sanofi & Teva Pharma’s RELIEVE UCCD phase 2b study of duvakitug in ulcerative colitis and Crohn’s disease meets primary endpoints: Paris Thursday, December 19, 2024, 11:00 Hrs ...

Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting ...

Sanofi SNY and partner Teva Pharmaceuticals TEVA announced positive data from the phase IIb RELIEVE UCCD study on their ...

Sanofi and Teva Pharmaceuticals have reported that the Phase IIb RELIEVE UCCD study of the human IgG1-λ2 monoclonal antibody ...

Teva Pharmaceutical (NYSE: TEVA) and Sanofi (NASDAQ: SNY) stocks were rising on Tuesday after the companies announced successful results of a phase 2 study involving the treatment of patients with ...

Teva Pharmaceutical (NYSE:TEVA) and Sanofi (NASDAQ:SNY) stocks were rising on Tuesday after the companies announced successful results of a phase 2 study involving the treatment of patients with ...

Jonathan Marchessault and Adam Wilsby scored and Juuse Saros made 25 saves to lead the Nashville Predators to a 2-0 victory over the New York Rangers on Tuesday night. The ...

Duvakitug（曾用名TEV’574）是一款潜在“best-in-class”的人源IgG1-λ2单抗，靶向TL1A，又称肿瘤坏死因子（TNF）超家族成员15。TL1A通过与其受体DR3结合，可放大炎症反应并加速IBD相关纤维化的进展。靶向TL1 ...